Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer

BMC Immunology

Research Article

Jing Li¹  Zhiwei Hu² 

[1] Department of Molecular Biophysics and Biochemistry, Yale University, 06520, New Haven, CT, USA;Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University, 06520, New Haven, CT, USA;Department of Molecular Biophysics and Biochemistry, Yale University, 06520, New Haven, CT, USA;

关键词: Natural Killer;    Natural Killer Cell;    SCID Mouse;    Complement Dependent Cytotoxicity;    Beige Mouse;   

DOI  :  10.1186/1471-2172-11-49

 received in 2010-04-28, accepted in 2010-10-12,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundIcon is a novel, dual neovascular- and cancer cell-targeting immunotherapeutic agent and has shown efficacy in the treatment of cancer, wet form macular degeneration and endometriosis. However, its underlying mechanism remains to be investigated. The objective of this study is to elucidate the mechanism of Icon immunotherapy in cancer using a squamous carcinoma human tongue cancer line TCA8113 in vitro and in vivo in severe combined immunodeficiency (SCID) mice.ResultsWe showed that Icon, as a chimeric factor VII and human IgG1 Fc immunoconjugate, could separately induce murine natural killer (NK) cells and activate complement to kill TCA8113 cancer cells in vitro via antibody dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, Icon-NK ADCC had a significantly stronger effect than that of Icon-CDC. Moreover, Icon could completely eradicate established human tongue tumour xenografts in vivo in the CB-17 strain of SCID mice that have functional NK cells at a normal level, whereas it was less effective in SCID/Beige mice that do not have functional NK cells.ConclusionsWe conclude that NK cells are crucial for the efficacy of Icon immunotherapy in the treatment of cancer. The results also suggest that impaired NK level/activity could contribute to the resistance to therapeutic antibodies that are currently under investigation in preclinical and clinical studies.

【 授权许可】

CC BY   
© Hu and Li; licensee BioMed Central Ltd. 2010